Table of Contents List of Tables List of Figures Introduction Global Markets Direct Report Coverage Pyelonephritis - Overview Pyelonephritis - Therapeutics Development Pipeline Overview Pipeline by Companies Products under Development by Companies Pyelonephritis - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Pyelonephritis - Companies Involved in Therapeutics Development Achaogen Inc AstraZeneca Plc Entasis Therapeutics Inc Meiji Seika Pharma Co Ltd Melinta Therapeutics Inc Merck & Co Inc MerLion Pharmaceuticals Pte Ltd Paratek Pharmaceuticals Inc Zavante Therapeutics Inc Pyelonephritis - Drug Profiles (AAI-101 + cefepime) - Drug Profile Product Description Mechanism Of Action R&D Progress (avibactam + ceftazidime) - Drug Profile Product Description Mechanism Of Action R&D Progress (ceftolozane sulfate + tazobactam sodium) - Drug Profile Product Description Mechanism Of Action R&D Progress (meropenem + vaborbactam) - Drug Profile Product Description Mechanism Of Action R&D Progress ETX-2514 + sulbactam sodium - Drug Profile Product Description Mechanism Of Action R&D Progress finafloxacin - Drug Profile Product Description Mechanism Of Action R&D Progress fosfomycin tromethamine - Drug Profile Product Description Mechanism Of Action R&D Progress nacubactam - Drug Profile Product Description Mechanism Of Action R&D Progress omadacycline - Drug Profile Product Description Mechanism Of Action R&D Progress plazomicin sulfate - Drug Profile Product Description Mechanism Of Action R&D Progress sulopenem - Drug Profile Product Description Mechanism Of Action R&D Progress Pyelonephritis - Dormant Projects Pyelonephritis - Discontinued Products Pyelonephritis - Product Development Milestones Featured News & Press Releases Feb 27, 2018: Melinta Therapeutics Publishes Complete Results from Phase 3 TANGO I Study of VABOMERE (meropenem and vaborbactam) in Patients with cUTI Jan 30, 2018: Achaogen Announces Upgraded Status for Plazomicin Fill Manufacturer Oct 26, 2017: Achaogen Submits Plazomicin New Drug Application (NDA) to the U.S. FDA for Treatment of Complicated Urinary Tract Infections and Bloodstream Infections Oct 05, 2017: The Medicines Company to Present New Data from TANGO II Study of VABOMERE™ (meropenem and vaborbactam) at IDWeek 2017 Oct 05, 2017: Achaogen IDWeek 2017 Presentations Feature Plazomicin’s Unique Potential to Treat MDR Enterobacteriaceae Oct 04, 2017: Merck Highlights Data on ZERBAXA at ID Week 2017 Sep 27, 2017: Achaogen Announces Multiple Plazomicin Presentations at IDWeek 2017 Aug 30, 2017: The Medicines Company Announces FDA Approval of VABOMERE (meropenem and vaborbactam) Jun 05, 2017: Achaogen Highlights Data Demonstrating Potential of Plazomicin Against MDR Gram-Negative Bacteria at ASM Microbe 2017 Annual Meeting Apr 17, 2017: The Medicines Company to Present Data at ECCMID 2017 on Infectious Disease Portfolio Including Investigational Antibiotic Meropenem-Vaborbactam Jan 30, 2017: FDA Approves Allergan's sNDA for AVYCAZ (ceftazidime and avibactam) to include new Phase III data in Patients with Complicated Urinary Tract Infections, Including Pyelonephritis Oct 26, 2016: Merck Highlights Data Presentation on ZERBAXA at ID Week 2016 Oct 11, 2016: FDA Accepts Supplemental New Drug Application (sNDA) for AVYCAZ (ceftazidime and avibactam) Jun 28, 2016: New antibiotic Zavicefta approved in the European Union for patients with serious bacterial infections Jun 15, 2016: Merck Presents Data on ZERBAXA (ceftolozane and tazobactam) at ASM Microbe 2016 Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer

List of Tables Number of Products under Development for Pyelonephritis, H1 2018 Number of Products under Development by Companies, H1 2018 Products under Development by Companies, H1 2018 Number of Products by Stage and Target, H1 2018 Number of Products by Stage and Mechanism of Action, H1 2018 Number of Products by Stage and Route of Administration, H1 2018 Number of Products by Stage and Molecule Type, H1 2018 Pyelonephritis - Pipeline by Achaogen Inc, H1 2018 Pyelonephritis - Pipeline by AstraZeneca Plc, H1 2018 Pyelonephritis - Pipeline by Entasis Therapeutics Inc, H1 2018 Pyelonephritis - Pipeline by Meiji Seika Pharma Co Ltd, H1 2018 Pyelonephritis - Pipeline by Melinta Therapeutics Inc, H1 2018 Pyelonephritis - Pipeline by Merck & Co Inc, H1 2018 Pyelonephritis - Pipeline by MerLion Pharmaceuticals Pte Ltd, H1 2018 Pyelonephritis - Pipeline by Paratek Pharmaceuticals Inc, H1 2018 Pyelonephritis - Pipeline by Zavante Therapeutics Inc, H1 2018 Pyelonephritis - Dormant Projects, H1 2018 Pyelonephritis - Discontinued Products, H1 2018List of Figures Number of Products under Development for Pyelonephritis, H1 2018 Number of Products under Development by Companies, H1 2018 Number of Products by Top 10 Targets, H1 2018 Number of Products by Stage and Top 10 Targets, H1 2018 Number of Products by Top 10 Mechanism of Actions, H1 2018 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018 Number of Products by Routes of Administration, H1 2018 Number of Products by Stage and Routes of Administration, H1 2018 Number of Products by Stage and Molecule Types, H1 2018